【Destiny Pharma-Product XF-73】Expansion of Clinical Pipeline

Partner News

27th September,
2021 – Destiny Pharma
issued an announcement,
which is summarized as follows: 

Expansion of clinical

New XF-73 skin
infection clinical programme planned to start in China led by existing partner,
China Medical System Holdings Limited

Targeting prevention
and treatment of superficial skin infections caused by bacteria

Destiny Pharma today announces that its China regional partner and investor,
China Medical System Holdings Limited (CMS), is establishing a new programme
with XF-73 targeting the prevention and treatment of superficial skin
infections caused by bacteria.

The programme will be
run in China and will be focused on delivering a novel product in the local
regulatory environment. The project will be led, managed and funded by CMS.
Destiny Pharma will contribute scientific advice as required through a steering
committee to the expert dermatology team at CMS. CMS has an extensive portfolio
of dermatology assets and an expert understanding of the market and its
requirements through its existing sales and marketing infrastructure.

Destiny Pharma has
cross-reference rights to data generated from the programme and, in the future,
could start a similar skin infection clinical programme focused on commercial
territories outside those held by CMS (China and other Asian countries
excluding Japan).

Destiny Pharma is
currently running its own dermal programme with XF-73 in a different indication
targeting the prevention and treatment of serious infections associated with
burns and open wounds.  This programme is
in collaboration with both the US government’s National Institute of Allergy
and Infectious Diseases (NIAID), and as part of the Global AMR Innovation Fund
(GAMRIF) funded UK-China bilateral partnership to tackle AMR which is managed
by Innovate UK. This new CMS initiative adds a further, differentiated product
to Destiny Pharma’s pipeline, leveraging off the very strong efficacy,
formulation and safety package generated to date by the XF platform.

Neil Clark, Chief
Executive Officer of Destiny Pharma said: “We are very pleased to announce the
addition of this new XF-73 dermal clinical programme to our portfolio with our
partner China Medical System Holdings Limited. We are looking forward to the
future development of this programme as well as our other infection prevention
assets as we continue to build a high quality, late-stage biotechnology

Original website Link:

27 September 2021 – Expansion of clinical pipeline